Challenges of Xpert MTB/RIF Assay: Insights from Four Clinical Cases

Overview

The Xpert MTB/RIF assay, while recommended for rapid tuberculosis diagnosis and rifampin resistance detection, has limitations demonstrated by four clinical cases. False-positive and false-negative results can lead to inappropriate treatment, highlighting the need for confirmatory testing and careful interpretation.

Background

Tuberculosis remains a major global health threat, with millions affected annually and a significant proportion exhibiting multidrug or rifampin resistance. Rapid molecular diagnostics like the Cepheid Xpert MTB/RIF assay detect MTB complex DNA and rifampin resistance mutations in the rpoB gene, expediting treatment decisions. Despite WHO recommendations endorsing its use for pulmonary and extrapulmonary specimens, the assay's limitations necessitate follow-up with culture, phenotypic susceptibility testing, and sequencing to ensure accurate diagnosis and appropriate therapy.

Data Highlights

Case 1: A 38-year-old woman with renal TB had a false-positive rifampin resistance result by Xpert MTB/RIF; sequencing revealed a silent rpoB mutation and phenotypic testing confirmed rifampin susceptibility.
Case 2: A 75-year-old kidney transplant recipient with disseminated TB had positive AFB smears and MTB/RIF PCR results; further details pending.
Additional cases illustrate discrepancies between molecular and phenotypic resistance results, underscoring assay limitations.

Key Findings

• The Xpert MTB/RIF assay can yield false-positive rifampin resistance results due to silent mutations in the rpoB gene.
• Phenotypic drug susceptibility testing and DNA sequencing remain essential to confirm molecular assay findings.
• False resistance detection may lead to unnecessary use of second-line anti-TB drugs, increasing patient risk and healthcare costs.
• Clinical scenarios involving extrapulmonary specimens require cautious interpretation of Xpert results due to variable assay performance.
• Laboratory oversight and confirmatory testing protocols are critical to avoid misdiagnosis and inappropriate treatment.

Clinical Implications

Clinicians should be aware of the potential for false-positive rifampin resistance results with the Xpert MTB/RIF assay and ensure confirmatory phenotypic and molecular testing before modifying treatment regimens. Careful interpretation of assay results, especially in extrapulmonary TB cases, can prevent unnecessary exposure to toxic second-line drugs and optimize patient outcomes.

Conclusion

While the Xpert MTB/RIF assay offers rapid TB diagnosis and rifampin resistance detection, its limitations necessitate confirmatory testing to guide appropriate therapy. Integrating molecular results with clinical and phenotypic data is essential for accurate diagnosis and effective management.

References

1. CDC 2023 -- Tuberculosis Epidemiology and Drug Resistance
2. WHO 2011 -- Policy Recommendations for Xpert MTB/RIF Implementation
3. WHO 2023 -- Guidelines for Molecular TB Diagnostics
4. MDDR Service Reports -- Molecular Detection of Drug Resistance